Results 161 to 170 of about 1,651 (200)

A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial. [PDF]

PLoS One
Aneheim E, Bäck T, Jensen H, Palm S, Lindegren S.   +4 more
europepmc   +1 more source

Highlight selection of radiochemistry and radiopharmacy developments by editorial board. [PDF]

EJNMMI Radiopharm Chem
Toyohara J, Elsinga PH, Todde S, Li XG, Aime S, Szymanski WC, van der Meulen N, Cleeren F, Schirrmacher R, Yang H, Savio E, Bentaleb N, Zubillaga M, Chaple Gore IF, Bourgeois M, Mukherjee A, Pellico J, Kopka K.   +17 more
europepmc   +1 more source

Clinical Application of Targeted Alpha Therapy Using Astatine (²¹¹At) —PSMA Targeted Alpha Therapy for Prostate Cancer—

Tadashi Watabe
openalex   +2 more sources

Fine-Tuning Radioimmunotherapy with an Alpha-Emitting Radionuclide [PDF]

, 2013
Morris, Valerie
core  

ICPO Forum 2025: advancing theranostics in precision oncology. [PDF]

Lancet Reg Health Eur
Baum RP, Jaume O.
europepmc   +1 more source

Scale-up production of [²¹¹At]PSMA-5 using automated synthesizer for Investigator-Initiated clinical trial. [PDF]

EJNMMI Radiopharm Chem
Naka S, Watabe T, Shirakami Y, Ooe K, Kurimoto K, Sakai T, Toyoshima A, Murakami M, Kon Y, Haba H, Cardinale J, Giesel FL, Isohashi K, Tomiyama N.   +13 more
europepmc   +1 more source

Modelling single cell dosimetry and DNA damage of targeted alpha therapy using Monte-Carlo techniques. [PDF]

Phys Eng Sci Med
Jolly AL, Fielding AL.
europepmc   +1 more source

First-in-human SPECT/CT imaging of [²¹¹At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Watabe T, Hatano K, Naka S, Sasaki H, Kamiya T, Shirakami Y, Toyoshima A, Cardinale J, Giesel FL, Isohashi K, Nonomura N, Tomiyama N.   +11 more
europepmc   +1 more source

211Atヒョウシキキンナノリュウシケツゴウコウタイヲモチイタアルファセンカクイガクチリョウヤクノカイハツケンキュウオヨビチソケトンショクブツカラタンリサレタリモノイドノコウエンショウサヨウニカンスルケンキュウ [PDF]

Hilmayanti, Erina, ヒルマヤンティ, エリナ   +1 more
core  

Novel astatine (²¹¹At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. [PDF]

Eur J Nucl Med Mol Imaging
Yaginuma K, Takahashi K, Hoshi S, Joho T, Shimoyama S, Hasegawa N, Hasegawa K, Zhao S, Ukon N, Makabe S, Meguro S, Onagi A, Matsuoka K, Ogawa S, Uemura M, Yamashita T, Suzuki H, Uehara T, Kojima Y.   +18 more
europepmc   +1 more source